ArticleWorld journal of gastroenterology2025
Retreatment hepatitis B surface antigen clearance prediction model identifies pegylated interferon alpha candidates in chronic hepatitis B.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFNα-2b.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B (CHB) patients rarely achieve functional cure with initial pegylated interferon alpha-2b (Peg-IFNα-2b) therapy. Validated tools to guide retreatment candidates are lacking. We hypothesized that clinical indicators predict hepatitis B surface antigen (HBsAg) clearance during retreatment.
aimTo develop a prediction model for HBsAg clearance in Peg-IFNα-2b retreatment.
methodsIn this retrospective cohort study, we enrolled 135 CHB/compensated cirrhosis patients receiving Peg-IFNα-2b retreatment after initial non-clearance at Tianjin University Central Hospital (2017-2025). Predictors were identified through univariate Cox, least absolute shrinkage and selection operator, and multivariate Cox regression. Model performance was assessed
resultsHBsAg clearance rate was 20.74% (28/135). Independent predictors included: Combination nucleos(t)ide analogue (NA) therapy during initial treatment [hazard ratio (HR) = 0.276, 95% confidence interval (CI): 0.092-0.833], baseline HBsAg at retreatment (HR = 0.571, 95%CI: 0.410-0.795), HBsAg decline after initial treatment (HR = 2.050, 95%CI: 1.108-3.793), and treatment interval (HR = 1.013/week, 95%CI: 1.008-1.018). The retreatment HBsAg clearance prediction score (RHCP-S) demonstrated area under the curve of 0.920 (95%CI: 0.863-0.946), sensitivity of 92.3%, specificity of 79.3%. Clearance rates differed significantly: RHCP-S challenge group (≤ 74 points): 3.45%, RHCP-S probable group (74-110 points): 29.63%, RHCP-S dominant group (≥ 110 points): 80.95% (
conclusionThe overall HBsAg clearance rate with Peg-IFNα-2b retreatment was 20.74% (28/135). The RHCP-S model identifies optimal retreatment candidates (≥ 110 points) with 80.95% clearance probability, associated with the absence of combination NA therapy during initial treatment, greater initial HBsAg decline, longer intervals, and lower retreatment HBsAg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.